CSIMarket
 


Rapid Therapeutic Science Laboratories Inc   (PCHA)
Other Ticker:  
 

Cumulative Rapid Therapeutic Science Laboratories Inc 's Working Capital Ratio for Trailing Twelve Months Period

PCHA's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

PCHA Working Capital Ratio for Trailing Twelve Months Period

(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
Y / Y Current Liabilities Growth -8.95 % -12.91 % 62.65 % 139.8 % 941.93 %
Y / Y Current Assets Growth -10.23 % -10.22 % -44.37 % -79.49 % 64.92 %
Working Capital Ratio for Trailing Twelve Months Period 0.06 0.06 0.06 0.07 0.15
Total Ranking # 4138 # 4329 # 4963 # 4739 # 5535
Seq. Current Liabilities Growth -0.83 % -10.13 % 1.24 % 0.92 % -5.15 %
Seq. Current Assets Growth 26.76 % 7.54 % -1.84 % -32.91 % 26.78 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Jun 30 2023
On the trailing twelve months basis Despite year on year decrease in Rapid Therapeutic Science Laboratories Inc 's average Current Liabilities to $4 millions, Working Capital Ratio for Trailing Twelve Months Period to 0.06 below company average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 512 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Rapid Therapeutic Science Laboratories Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about PCHA
Working Capital Ratio PCHA in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 513
Sector # 1061
S&P 500 # 4086


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
0.61 0.15 0
(Sep 30 2021)   (Mar 31 2019)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Bespoke Extracts Inc   0.15 
Emmaus Life Sciences Inc   0.15 
Altamira Therapeutics Ltd   0.14 
Scopus Biopharma Inc   0.13 
Northwest Biotherapeutics inc  0.11 
Cnbx Pharmaceuticals Inc   0.10 
Agex Therapeutics Inc   0.10 
Cytodyn inc   0.09 
Viveon Health Acquisition Corp   0.09 
Aeon Biopharma inc   0.09 
Bioxytran Inc   0.07 
Statera Biopharma Inc fka Cytocom Inc   0.07 
Intellipharmaceutics International Inc   0.07 
Cell Source Inc   0.06 
Sangui Biotech International Inc  0.06 
Rapid Therapeutic Science Laboratories Inc   0.06 
Wellness Center Usa Inc  0.04 
Earth Science Tech Inc   0.04 
Regen Biopharma Inc  0.04 
Actavia Life Sciences Inc   0.03 
Skinvisible Inc   0.03 
Innovation1 Biotech Inc   0.03 
Axim Biotechnologies Inc   0.03 
Biostax Corp  0.03 
Cen Biotech Inc  0.03 
Novaccess Global Inc   0.03 
Bioadaptives Inc   0.02 
Oncotelic Therapeutics Inc   0.02 
Rebus Holdings Inc   0.02 
Theralink Technologies Inc   0.02 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com